01:09 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

sterna's SB012 meets in Phase IIa data for UC

sterna biologicals GmbH & Co. KG (Marburg, Germany) said intrarectal SB012 met the primary endpoint of improving disease activity from baseline to day 28 as measured by total Mayo Score vs. placebo in the Phase...
20:32 , May 23, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles sensitive to endosomal esterases and linked to DNA oligomers could be used to deliver hydrophobic drug compounds and/or nucleic acid therapies for multiple diseases. The nanoparticles consisted of an internal surfactant micelle...
07:00 , May 7, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer ...